Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

The Lancet Oncology

Volumn 19, Issue 12, 2018, Pages 1579-1589

  Salem, Joe Elie ^a,b   Manouchehri, Ali ^b   Moey, Melissa ^b   Lebrun Vignes, Bénédicte ^a   Bastarache, Lisa ^b   Pariente, Antoine ^c   Gobert, Aurélien ^a   Spano, Jean Philippe ^a   Balko, Justin M ^b   Bonaca, Marc P ^d   Roden, Dan M ^b   Johnson, Douglas B ^b   Moslehi, Javid J ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AXITINIB; BENDAMUSTINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DURVALUMAB; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; NIRAPARIB; NIVOLUMAB; OBINUTUZUMAB; PACLITAXEL; PEMBROLIZUMAB; TEMOZOLOMIDE; TRAMETINIB; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADULT; ADVERSE OUTCOME; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; BLEEDING; BLINDNESS; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOVASCULAR TOXICITY; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COLITIS; CONTROLLED STUDY; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; ENCEPHALITIS; ENDOCARDIAL DISEASE; ENTERITIS; FEMALE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART TAMPONADE; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYPERTENSION; HYPOPHYSITIS; KIDNEY DISEASE; LEUKOPENIA; LICHEN PLANUS; LIVER FAILURE; LUNG CANCER; LUNG DISEASE; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENINGITIS; METABOLIC DISORDER; MONOTHERAPY; MORTALITY RATE; MUSCULOSKELETAL DISEASE; MYASTHENIA GRAVIS; MYOCARDITIS; MYOSITIS; NEPHRITIS; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PATIENT CARE; PEMPHIGUS; PERICARDIAL DISEASE; PERICARDIAL EFFUSION; PERICARDITIS; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; PURPURA; QT PROLONGATION; RASH; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK FACTOR; STEVENS JOHNSON SYNDROME; TEMPORAL ARTERITIS; THROMBOCYTOPENIA; THYROID DISEASE; TORSADE DES POINTES; TOXICITY; VASCULAR TUMOR; VASCULITIS; BAYES THEOREM; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; FACTUAL DATABASE; IMMUNOTHERAPY; MIDDLE AGED; RISK ASSESSMENT; TIME FACTOR; VERY ELDERLY;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BAYES THEOREM; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PHARMACOVIGILANCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 85058593629     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30608-9     Document Type: Article

References (31)

1. Postow, MA, Callahan, MK, Wolchok, JD, Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
2. Ribas, A, Wolchok, JD, Cancer immunotherapy using checkpoint blockade. Science 359 (2018), 1350–1355.
3. Johnson, DB, Balko, JM, Compton, ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
4. Moslehi, JJ, Salem, JE, Sosman, JA, Lebrun-Vignes, B, Johnson, DB, Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet, 391, 2018, 933.
5. Escudier, M, Cautela, J, Malissen, N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136 (2017), 2085–2087.
6. Mahmood, SS, Fradley, MG, Cohen, JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 (2018), 1755–1764.
7. Lindquist, M, VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 42 (2008), 409–419.
8. Bate, A, Lindquist, M, Edwards, IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54 (1998), 315–321.
9. Noren, GN, Hopstadius, J, Bate, A, Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22 (2013), 57–69.
10. De Bruin, ML, Pettersson, M, Meyboom, RH, Hoes, AW, Leufkens, HG, Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26 (2005), 590–597.
11. Rothman, KJ, Lanes, S, Sacks, ST, The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13 (2004), 519–523.
12. Grouthier, V, Lebrun-Vignes, B, Glazer, AM, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart 104 (2018), 1859–1863.
13. Postow, MA, Sidlow, R, Hellmann, MD, Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378 (2018), 158–168.
14. Varricchi, G, Marone, G, Mercurio, V, Galdiero, MR, Bonaduce, D, Tocchetti, CG, Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem 25 (2018), 1327–1339.
15. Conforti, F, Pala, L, Bagnardi, V, et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncol 19 (2018), 737–746.
16. Wu, Y, Ju, Q, Jia, K, et al. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). Int J Cancer 143 (2018), 45–51.
17. Nishimura, H, Okazaki, T, Tanaka, Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291 (2001), 319–322.
18. Varricchi, G, Galdiero, MR, Tocchetti, CG, Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology. Circulation 136 (2017), 1989–1992.
19. Arangalage, D, Delyon, J, Lermuzeaux, M, et al. Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 167 (2017), 683–684.
20. Nasr, F, El Rassy, E, Maalouf, G, et al. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer 91 (2018), 171–173.
21. Frigeri, M, Meyer, P, Banfi, C, et al. Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol 34 (2018), 92.e1–92.e3.
22. Herbst, RS, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
23. Sharabi, AB, Lim, M, DeWeese, TL, Drake, CG, Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16 (2015), e498–e509.
24. Imazio, M, Demichelis, B, Parrini, I, et al. Relation of acute pericardial disease to malignancy. Am J Cardiol 95 (2005), 1393–1394.
25. Tocut, M, Brenner, R, Zandman-Goddard, G, Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17 (2018), 610–616.
26. Hid Cadena, R, Abdulahad, WH, Hospers, GAP, et al. Checks and balances in autoimmune vasculitis. Front Immunol, 9, 2018, 315.
27. Kamesh, L, Heward, JM, Williams, JM, et al. CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis. Rheumatology 48 (2009), 1502–1505.
28. Langford, CA, Cuthbertson, D, Ytterberg, SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69 (2017), 837–845.
29. Watanabe, R, Zhang, H, Berry, G, Goronzy, JJ, Weyand, CM, Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 312 (2017), H1052–H1059.
30. Salvarani, C, Cimino, L, Macchioni, P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53 (2005), 293–297.
31. Wang, DY, Salem, JE, Cohen, JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol, 2018 published online Sept 13. DOI:10.1001/jamaoncol.2018.3923.